Seres Therapeutics, Inc. (NASDAQ:MCRB) Q3 2023 Results Conference Call November 2, 2023 8:00 AM ET

Company Participants

Kevin Mannix - Head, IR

Eric Shaff - CEO

Dr. Terri Young - Chief Commercial Officer

David Arkowitz - CFO

Conference Call Participants

Joseph Thome - TD Cowen

Edward Tenthoff - Piper Sandler

Tessa Romero - JPMorgan

Jeff Jones - Oppenheimer

Keay Nakae - Chardan

Stephen Sloan - Goldman Sachs

Operator

Welcome to the Seres Therapeutics Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Kevin Mannix, Head of Investor Relations. Please go ahead.

Kevin Mannix

Thank you, Dave, and good morning, everyone. Our press release for the company’s third quarter 2023 financial results and business update became available at 7:00 a.m. Eastern Time this morning, and can be found on the Investor and News section of the company’s website.

I’d like to remind you that we’ll be making forward-looking statements, including the availability of cash to fund operations, the potential sales for VOWST, the timing and results of clinical studies, our ability to achieve sales targets and other statements, which are not historical fact. Actual results may differ materially.

Additionally, these statements are subject to certain risks and uncertainties, which are discussed under the Risk Factors section of our SEC filings. Any forward-looking statements made on today’s call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so.

On today’s call with prepared remarks, I’m joined by Eric Shaff, Seres’ Chief Executive Officer; Dr. Terri Young, Chief Commercial Officer; and David Arkowitz, Chief Financial Officer. In addition, Dr. Matthew Henn, Chief Scientific Officer; Dr. Lisa von Moltke, Chief Medical Officer, CMO, and Dr. Dave Ege, Chief Technology Officer, will also be available to address questions.

With that, I’ll now pass the call over to Eric Shaff. Eric, please?

Eric Shaff

Thank you, Kevin, and good morning, everyone. By now, I hope you have all had the opportunity to read our press release, including the continued strong VOWST launch performance and our decision to implement a strategic restructuring.

Since the beginning of the year, the innovation and perseverance of our team has been extraordinary, culminating with the approval and commercialization of VOWST in collaboration with Nestle Health Science. Everything we do at Seres has and always will be driven by a desire to support patients with unmet medical needs. It is the hope and resilience of each patient and their families that inspires us and drives us to fulfill our mission. VOWST is the perfect example of this.